This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

Nimenrix for Travel

Nimenrix (meningococcal groups A, C, W-135 and Y conjugate vaccine) is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.1

When people travelling are at risk of meningococcal ACWY disease, help protect them with Nimenrix.1,2

Meningococcal ACWY vaccination is a requirement for Hajj and Umrah pilgrims3

All people travelling to the Kingdom of Saudi Arabia for Hajj or Umrah (including seasonal workers) require proof of Meningococcal ACWY vaccination for entry.3

In 2017 over 25,000 British nationals performed Hajj and around 100,000 the pilgrimage of Umrah.4

Meningococcal ACWY vaccination is recommended for some people travelling to the ‘meningitis belt’ of sub-Saharan Africa.2

Outbreaks of meningococcal meningitis in the meningitis belt can reach epidemic proportions during the dry season (December to June).2

Meningococcal ACWY vaccination may also be recommended for long-stay travellers  likely to have close contact with the local population, such as:2

  • Backpackers
  • People visiting friends and relatives
  • Aid or health workers

Countries in Africa where vaccination against meningococcal disease is recommended for some travellers:5

Countries

Benin

Ethiopia

Nigeria

Burkino Faso

The Gambia

Rwanda

Burundi

Ghana

Senegal

Cameroon

Guinea

South Sudan

Central Africa Republic

Guinea Bissau

Sudan

Chad

Kenya

Tanzania

Côte d’Ivoire

Mali

Togo

Democratic Republic of Congo

Mauritania

Uganda

Eritrea

Niger

Why choose Nimenrix for meningococcal ACWY vaccination?

  • ​​​​​​​Nimenrix can be used to help protect a broad age range of people
    • The only meningococcal conjugate ACWY vaccine approved for use from 6 weeks of age, with no upper age limit.*​​​​​​​1
  • The first and only ACWY meningococcal conjugate vaccine with antibody persistence evaluated for up to 10 years.1
    • 10 years following Nimenrix vaccination, a proportion of individuals vaccinated at 12-23 months of age and the majority of individuals vaccinated at 2-55 years of age maintained seroprotection (rSBA titres ≥=1:8) for serogroups A, C, W and Y.
  • Nimenrix has a well established safety profile evaluated in clinical studies of over 10,000 individuals.1
  • Nimenrix is supplied with the solvent in a pre-filled syringe, powder in a vial and two needles. 6
  • Nimenrix is certified Halal by the Halal Food Council of Europe. 7
*Note, infants from 6 weeks to less than 6 months of age: two doses, each of 0.5 ml, should be administered with an interval of 2 months between doses. A booster dose should be given at 12 months of age with an interval of at least 2 months after the last Nimenrix vaccination.

See the Nimenrix Summary of Product Characteristics for further details on dosage.

References
  1. Nimenrix. Summary of Product Characteristics, United Kingdom, Pfizer Ltd. Available here
  2. TravelHealthPro. Meningococcal Disease fact sheet. Available here (last accessed March 2021).
  3. Travel Health Pro. Hajj and Umrah. Available here (last accessed March 2021).
  4. The Council of British Hajjis UK (CBHUK). Hajj Debrief calls on the industry to join forces in serving British pilgrims. Available here (last accessed March 2021). 
  5. Pulse. Travel Medicine Guide (updated March 2020).
  6. Pfizer Data on File, November 2018. 
  7. Pfizer Data on File, November 2016.
PP-NIM-GBR-0249. March 2021

E-Learning Modules 

Access E-Learning modules for our Vaccines brands

Access Now

Ask Pfizer

Contact our Pfizer Vaccines UK team 

Contact Us

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No